Antiviral activity against Human respiratory syncytial virus A2 infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 5 days using crystal violet staining
Antiviral activity against Human respiratory syncytial virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
Antiviral activity against Respiratory syncytial virus A2 infected in human Hep2 cells assessed as reduction of virus-induced cytopathic effect after 4 days by Cell-Titer Glo assay
Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay
Antiviral activity against human respiratory syncytial virus A2 infected in po dosed Balb/c mouse assessed as reduction in lung viral load administered once daily pretreated for 1 hr on day 0 followed by viral infection and subsequent compound dosing for 3 days measured after 1 day post last dose by plaque assay
Antiviral activity against human respiratory syncytial virus A2 infected in Balb/c mouse assessed as reduction in lung viral load at 50 mg/kg, po administered once daily pretreated for 1 hr on day 0 followed by viral infection and subsequent compound dosing for 3 days measured after 1 day post last dose by plaque assay
Antiviral activity against human respiratory syncytial virus A2 infected in Balb/c mouse assessed as reduction in lung viral load at 5 mg/kg, po administered once daily pretreated for 1 hr on day 0 followed by viral infection and subsequent compound dosing for 3 days measured after 1 day post last dose by plaque assay
Antiviral activity against human respiratory syncytial virus A2 infected in Balb/c mouse assessed as reduction in lung viral load at 15 mg/kg, po administered once daily pretreated for 1 hr on day 0 followed by viral infection and subsequent compound dosing for 3 days measured after 1 day post last dose by plaque assay
Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay
Antiviral activity against Human respiratory syncytial virus A2 infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by CellTiter-Glo viability reagent based assay
Antiviral activity against Human respiratory syncytial virus A2 infected in human Hep2 cells assessed as reduction in virus induced cytopathic effect after 5 days by CCK-8 assay